Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

Clinical trial NCT04005144 · TERMINATED

Trial details

NCT number: NCT04005144
Sponsor: University of California, San Francisco
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

ALK Gene Rearrangement Lung Non-Small Cell Carcinoma Progressive Disease ROS1 Gene Rearrangement Stage IIIB Lung Cancer Stage IIIC Lung Cancer Stage IV Lung Cancer Stage IVA Lung Cancer Stage IVB Lung Cancer

Start date: 2020-02-25
Primary completion: 2022-10-01
Enrollment: 3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.